Short Interest in Pharming Group (NASDAQ:PHAR) Drops By 29.3%

Pharming Group (NASDAQ:PHAR) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 5,300 shares, a drop of 29.3% from the January 31st total of 7,500 shares. Based on an average daily volume of 6,600 shares, the short-interest ratio is presently 0.8 days.

Analysts Set New Price Targets

Several research firms have weighed in on PHAR. HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a report on Tuesday, December 17th. Jefferies Financial Group assumed coverage on Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 target price for the company.

Pharming Group Trading Down 6.7 %

Shares of Pharming Group stock traded down $0.62 on Wednesday, reaching $8.63. The company had a trading volume of 10,713 shares, compared to its average volume of 5,950. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The firm has a market cap of $587.11 million, a PE ratio of -33.19 and a beta of -0.10. The firm’s 50 day moving average price is $9.29 and its two-hundred day moving average price is $8.56. Pharming Group has a 52-week low of $6.65 and a 52-week high of $11.94.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.